Cargando…
Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial
BACKGROUND: Recent EAU guideline strongly recommended combined targeted biopsy (TBx) with systematic biopsy (SBx) for biopsy naïve patients with suspected multiparametric magnetic resonance imaging (mpMRI) lesions; However, the clinical goal is to find out how to determine the optimal SBx and TBx co...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852774/ https://www.ncbi.nlm.nih.gov/pubmed/36684126 http://dx.doi.org/10.3389/fsurg.2022.1058288 |
_version_ | 1784872728610734080 |
---|---|
author | Zhang, Chichen Tu, Xiang Dai, Jindong Xiong, Xingyu Cai, Diming Yang, Ling Zhang, Mengni Qiu, Shi Lin, Tianhai Liu, Zhenhua Yang, Lu Wei, Qiang |
author_facet | Zhang, Chichen Tu, Xiang Dai, Jindong Xiong, Xingyu Cai, Diming Yang, Ling Zhang, Mengni Qiu, Shi Lin, Tianhai Liu, Zhenhua Yang, Lu Wei, Qiang |
author_sort | Zhang, Chichen |
collection | PubMed |
description | BACKGROUND: Recent EAU guideline strongly recommended combined targeted biopsy (TBx) with systematic biopsy (SBx) for biopsy naïve patients with suspected multiparametric magnetic resonance imaging (mpMRI) lesions; However, the clinical goal is to find out how to determine the optimal SBx and TBx cores for biopsy in order to maximize the detection of csPCa and minimize the associated defects. This study aims to assess the efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI- TBx compared to 12-core systematic and 3-core MRI-TBx strategy. METHODS: This is a single-center, prospectively randomized controlled clinical trial. 280 men meeting inclusion criteria will be recruited and will be randomly allocated to either 6-core systematic plus 3-core MRI-TBx group (Group A) or 12-core systematic plus 3-core MRI-TBx group (Group B). The primary outcome compares the detection rate of PCa and clinically significant prostate cancer(csPCa) between group A and group B. The secondary outcomes compare the participant-reported pain score immediate post biopsy using pain measurement scale; proportion of men with post-biopsy complications and adverse events (Time frame: 7 days post biopsy, 30 days post biopsy); proportion of the men who undergo radical prostatectomy and have cancer upgraded histopathology from the biopsy to the radical prostatectomy. RESULTS AND DISCUSSION: A new biopsy strategy should be developed with the goal of minimizing procedure invasion, our study will provide the results of efficacy and safety of the new biopsy strategy (6-core systematic and 3-core MRI-TBx) in biopsy naïve men with suspicious mpMRI lesion in comparison with 12-core systematic and 3-core MRI-TBx. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200056437; http://www.chictr.org.cn/edit.aspx?pid=151413&htm=4 |
format | Online Article Text |
id | pubmed-9852774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98527742023-01-21 Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial Zhang, Chichen Tu, Xiang Dai, Jindong Xiong, Xingyu Cai, Diming Yang, Ling Zhang, Mengni Qiu, Shi Lin, Tianhai Liu, Zhenhua Yang, Lu Wei, Qiang Front Surg Surgery BACKGROUND: Recent EAU guideline strongly recommended combined targeted biopsy (TBx) with systematic biopsy (SBx) for biopsy naïve patients with suspected multiparametric magnetic resonance imaging (mpMRI) lesions; However, the clinical goal is to find out how to determine the optimal SBx and TBx cores for biopsy in order to maximize the detection of csPCa and minimize the associated defects. This study aims to assess the efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI- TBx compared to 12-core systematic and 3-core MRI-TBx strategy. METHODS: This is a single-center, prospectively randomized controlled clinical trial. 280 men meeting inclusion criteria will be recruited and will be randomly allocated to either 6-core systematic plus 3-core MRI-TBx group (Group A) or 12-core systematic plus 3-core MRI-TBx group (Group B). The primary outcome compares the detection rate of PCa and clinically significant prostate cancer(csPCa) between group A and group B. The secondary outcomes compare the participant-reported pain score immediate post biopsy using pain measurement scale; proportion of men with post-biopsy complications and adverse events (Time frame: 7 days post biopsy, 30 days post biopsy); proportion of the men who undergo radical prostatectomy and have cancer upgraded histopathology from the biopsy to the radical prostatectomy. RESULTS AND DISCUSSION: A new biopsy strategy should be developed with the goal of minimizing procedure invasion, our study will provide the results of efficacy and safety of the new biopsy strategy (6-core systematic and 3-core MRI-TBx) in biopsy naïve men with suspicious mpMRI lesion in comparison with 12-core systematic and 3-core MRI-TBx. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200056437; http://www.chictr.org.cn/edit.aspx?pid=151413&htm=4 Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9852774/ /pubmed/36684126 http://dx.doi.org/10.3389/fsurg.2022.1058288 Text en © 2023 Zhang, Tu, Dai, Xiong, Cai, Yang, Zhang, Qiu, Lin, Liu, Yang and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Zhang, Chichen Tu, Xiang Dai, Jindong Xiong, Xingyu Cai, Diming Yang, Ling Zhang, Mengni Qiu, Shi Lin, Tianhai Liu, Zhenhua Yang, Lu Wei, Qiang Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title | Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title_full | Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title_fullStr | Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title_full_unstemmed | Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title_short | Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial |
title_sort | efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core mri-targeted biopsy in the detection of prostate cancer: study protocol for a randomized controlled trial |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852774/ https://www.ncbi.nlm.nih.gov/pubmed/36684126 http://dx.doi.org/10.3389/fsurg.2022.1058288 |
work_keys_str_mv | AT zhangchichen efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT tuxiang efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT daijindong efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT xiongxingyu efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT caidiming efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT yangling efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT zhangmengni efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT qiushi efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT lintianhai efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT liuzhenhua efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT yanglu efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial AT weiqiang efficacyandsafetyofthenewbiopsystrategycombining6coresystematicand3coremritargetedbiopsyinthedetectionofprostatecancerstudyprotocolforarandomizedcontrolledtrial |